Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial

Stéphanie Becker (1, 2) , Thomas Vermeulin (3) , Anne-Ségolène Cottereau (4) , Nicolas Boissel (5) , Pierre Vera (1, 2) , Stéphane Leprêtre (6)

1 Service de médecine nucléaire [Rouen]
2 QuantIF-LITIS - Equipe Quantification en Imagerie Fonctionnelle
3 Hôpital Charles Nicolle [Tunis]
4 UNIROUEN UFR Santé - UNIROUEN - UFR Santé
5 AP-HP - Hopital Saint-Louis [AP-HP]
6 GPL - Groupe d'étude des proliférations lymphoïdes

We examined whether FDG PET can be used to predict outcome in patients with lymphoblastic lymphoma (LL).

Mots clés: 18F-FDG; Chemotherapy; Clinical trial; Lymphoblastic lymphoma; PET/CT; Prognostic factors

Domaines: Sciences du Vivant [q-bio]

Stéphanie Becker, Thomas Vermeulin, Anne-Ségolène Cottereau, Nicolas Boissel, Pierre Vera, et al.. Predictive value of 18F-FDG PET/CT in adults with T-cell lymphoblastic lymphoma: post hoc analysis of results from the GRAALL-LYSA LLO3 trial. European Journal of Nuclear Medicine and Molecular Imaging, 2017, 44 (12), pp.2034 - 2041. ⟨10.1007/s00259-017-3776-3⟩. ⟨hal-01637149⟩